Skip to main content
XWEL
NASDAQ Trade & Services

XWELL Stockholders Approve $13M XpresSpa/XpresTest Sale and Plan Share Increase

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.69
Mkt Cap
$6.883M
52W Low
$0.255
52W High
$2.2
52W Position info
171% above low
Off High info
69% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

XWEL has more than doubled off its 52-week low of $0.255.

Summary

XWELL shareholders approved the $13 million sale of XpresSpa and XpresTest, along with a 1.22 million share increase to the 2020 equity plan. The divestiture now awaits closing.


Key Events · M&A and Partnerships · XWEL

  • Shareholders Approve Divestiture

    Proposal No. 1, adopting the July 6, 2026 Purchase Agreement and selling XpresSpa and XpresTest, passed 5,423,862 to 100,417, with 16,367 abstaining.

  • Equity Plan Reserve Increased

    Proposal No. 3 approved raising the 2020 Plan reserve from 3,125,000 to 4,346,134 shares — an additional 1,221,134 shares available for grants.

  • Golden Parachute Pay Approved

    Advisory Proposal No. 2 on change-in-control compensation for named executive officers passed 5,055,439 to 478,104.

  • Quorum Met at Special Meeting

    Of 10,620,883 outstanding shares, 5,708,101 were represented, 53.74% of voting power; adjournment was unnecessary.


Analysis · XWEL · Trade & Services

Shareholders have now approved the sale of XpresSpa and XpresTest — the company's core operating businesses — clearing the main condition to closing. For a company that just received a Nasdaq sub-$1.00 notice and reported a $2.24M quarterly loss with five material weaknesses, that is a thesis-level change. Approval of the 2020 Plan increase from 3,125,000 to 4,346,134 shares also expands the equity-compensation overhang by roughly 1.22 million shares. What remains is closing the transaction on the July 6, 2026 Purchase Agreement terms; the filing does not state a closing date.

How filings like this one have moved

In the 30 days to Nov 2, 2026, 32.7% of the 1910 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, XWEL was trading at $0.69 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $6.9M. The 52-week trading range was $0.26 to $2.20. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XWEL - Latest Insights

XWEL
Oct 20, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.7165
Real-time Price: $0.6901 info
Change: -$0.0264 (-4%) info
Market Cap: $6.881M info
XWEL
Oct 07, 2026, 8:44 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.850
Real-time Price: $0.6901 info
Change: -$0.1599 (-19%) info
Market Cap: $6.881M info
XWEL
Oct 07, 2026, 8:41 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.850
Real-time Price: $0.6901 info
Change: -$0.1599 (-19%) info
Market Cap: $6.881M info
XWEL
Sep 08, 2026, 8:00 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.9575
Real-time Price: $0.6901 info
Change: -$0.2674 (-28%) info
Market Cap: $6.881M info
XWEL
Aug 14, 2026, 4:15 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.980
Real-time Price: $0.6901 info
Change: -$0.2899 (-30%) info
Market Cap: $6.881M info